Serum Immunoglobulin (G) as a Marker of Diabetic Nephropathy

Serum Immunoglobulin (G ) as a Predictive Marker of Early Renal Affection in Type 2 Diabetic Patients

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03212755

Enrollment

Registered

2017-07-11

Start date

2017-08-31

Completion date

2019-12-31

Last updated

2017-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Nephropathies

Brief summary

Diabetes mellitus is a chronic disease that affects 366 million people worldwide ( 6.4 % of the adult population ) and is expected to rise to 522 million by 2030 . Diabetic nephropathy occurs in approximately one - third of all people with diabetes and is the leading cause of renal failure in developed and developing countries Diabetic nephropathy is a severe complication occurring in diabetic patients and it is associated with an increased risk of all- cause mortality , cardiovascular disease and progression to end stage renal disease , requiring costly renal replacement therapy in the form of dialysis or transplantation

Interventions

DIAGNOSTIC_TESTserum immunoglobulin G level

measurement of the serum level as a marker of diabetic complications

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SCREENING

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

30 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* type 2 diabetic patients

Exclusion criteria

* patients with diabetes type 1 , * pregnant and lactating females , * patients with any congenital disease , Infection , Smokers , alcoholics , and drug abusers .

Design outcomes

Primary

Measure	Time frame
The number of patients with high level of immunoglobulin in serum	24 hours

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026